Premium
Personal solar UV‐A doses received by patients undergoing oral psoralen photochemotherapy for psoriasis
Author(s) -
MOSELEY H.,
DIFFEY B.L.,
MARKS J.M.,
MACKIE R.M.
Publication year - 1981
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1981.tb00802.x
Subject(s) - psoralen , psoriasis , medicine , sunlight , dermatology , puva therapy , skin type , sun exposure , optics , chemistry , dna , biochemistry , physics
SUMMARY Patients undergoing oral psoralen photochemotherapy (PUVA) for psoriasis receive a known amount of UV‐A in the treatment cubicle and an unknown amount of UV‐A from sunlight. In order to measure the solar UV‐A dose, fifty‐six patients received a UV‐sensitive film badge to be worn from the time they took their psoralen tablet throughout the course of the day, except during treatment. The UV‐A doses measured in this way varied from less than 0.2 J cm ‐2 to 7 J cm ‐2 , with a median of around 1 J cm ‐2 . These results show that the solar UV‐A received by patients who have been photosensitized by 8‐MOP may not be insignificant in relation to the treatment dose.